Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof

Patent metadata

Field	Value
Publication number	US-11098060-B2
Application number	US-201816641187-A
Country	US
Kind code	B2
Filing date	Aug 23, 2018
Priority date	Aug 23, 2017
Publication date	Aug 24, 2021
Grant date	Aug 24, 2021

Abstract

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.

First claim

What is claimed is:

1. A compound of Formula (I)

or a pharmaceutically acceptable salt thereof, wherein
X is selected from the group consisting of a bond, —O—, —S—, and —NR 4 —;
Y is selected from the group consisting of

wherein “*” represents the end of the Y group attached to the aminopyrazolopyrimidine ring;
R 1 and R 2 are independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, nitro, hydroxy, cyano and amino, wherein C 1 -C 6 alkyl and C 1 -C 6 alkoxy are optionally substituted with one or more substituents independently selected from the group consisting of halo, nitro, hydroxy, cyano and amino; or
R 1 and R 2 are taken together to form (═O) or (═S);
R 3 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo, nitro, hydroxy, cyano and amino, wherein C 1 -C 6 alkyl and C 1 -C 6 alkoxy are optionally substituted with one or more substituents independently selected from the group consisting of halo, nitro, hydroxy, cyano and amino;
R 4 and R 5 are independently selected from the group consisting of hydrogen and C 1 -C 6 alkyl;
m is selected from 0, 1, 2, 3, 4, 5 or 6;
n is selected from 0, 1, 2, 3, 4, 5, 6 or 7;
Cy is selected from the group consisting of a 6- to 10-membered aromatic ring, a 5- to 10-membered aromatic heterocycle, a 3- to 10-membered aliphatic heterocycle, and a 3- to 10-membered cycloalkyl ring, wherein the 6- to 10-membered aromatic ring, 5- to 10-membered aromatic heterocycle, 3- to 10-membered aliphatic heterocycle, or 3- to 10-membered cycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 alkoxy, (═O), halo, nitro, hydroxy, cyano, and amino.

2. The compound according to claim 1 , wherein X is selected from the group consisting of a bond and —O—.

3. The compound according to claim 1 , wherein Y is selected from the group consisting of

wherein “*” represents the end of the Y group attached to the aminopyrazolopyrimidine ring.

4. The compound according to claim 1 , wherein R 5 is selected from the group consisting of hydrogen and C 1 -C 3 alkyl.

5. The compound according to claim 1 , wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, fluoro, chloro, bromo, iodo, nitro, hydroxy, cyano, and amino, wherein C 1 -C 3 alkyl and C 1 -C 3 alkoxy are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, nitro, hydroxy, cyano, and amino.

6. The compound according to claim 1 , wherein m is selected from 1, 2, 3, 4, or 5.

7. The compound according to claim 1 , wherein R 3 is selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkoxy, fluoro, chloro, bromo, iodo, nitro, hydroxy, cyano, and amino, wherein C 1 -C 3 alkyl and C 1 -C 3 alkoxy are optionally substituted with one or more substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, nitro, hydroxy, cyano, and amino.

8. The compound according to claim 1 , wherein n is selected from 0, 1, 2, or 3.

9. The compound according to claim 1 , wherein, Cy is selected from the group consisting of benzene ring, naphthalene ring, pyrrole, furan, thiophene, imidazole, oxazole, pyrazole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, isoindole, oxirane, tetrahydrofuran, dihydrofuran, pyrrolidine, dihydropyrrolidine, 2H-pyridine, piperidine, piperazine, pyrazolidine, tetrahydropyran, morpholine, thiomorpholine, tetrahydrothiophene, cyclopropane, cyclopentane, and cyclohexane, each of which is optionally substituted with one or more substituents independently selected from the group consisting of C 1 -C 3 alkyl, C 1 -C 3 alkoxy, (═O), fluoro, chloro, bromo, iodo, nitro, hydroxy, cyano, and amino.

10. The compound according to claim 1 , wherein the compound of Formula (I) is a compound represented by Formula (II),

wherein X, R 1 , R 2 , R 3 , R 5 , Cy, m and n are as defined in claim 1 .

11. The compound according to claim 1 , wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof is selected from the group consisting of

and a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound of Formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof.

13. A method for ameliorating, eliminating, inhibiting, alleviating, or combinations thereof, a disease mediated by Trk kinase in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of Formula (I) according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disease is a tumor.

14. The compound of claim 4 , wherein R 5 is selected from the group consisting of hydrogen and methyl.

15. The compound of claim 5 , wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, fluoro, and methyl.

16. The compound of claim 1 , wherein the structural unit

is selected from the group consisting of

wherein ** represents the end of the structural unit

attached to X.

17. The compound of claim 7 , wherein R 3 is selected from the group consisting of fluoro, chloro, bromo, iodo, and hydroxy.

18. The compound of claim 8 , wherein n is selected from 0 or 1.

19. The compound of claim 9 , wherein Cy is selected from the group consisting of a benzene ring, pyridine, and 1,2-2H-pyridine, each of which is optionally substituted with one or more substituents independently selected from the group consisting of fluoro and (═O).

20. The compound of claim 9 , wherein Cy is selected from the group consisting of

Assignees

• Chia Tai Tianqing Pharmaceutical Group Co Ltd
• Centaurus Biopharma Co Ltd
• Lianyungang Runzhong Pharmaceutical Co Ltd

Inventors

• Dai Liguang
• Duan Xiaowei
• Yang Yanqing
• Liu Xijie
• Li Hongjuan
• Zhao Na
• Sun Yinghui
• Kong Fansheng
• Zhang Jiuqing
• Zhu Yizhong
• Yang Ling
• Liu Fei

Classifications

• C07D498/22 Primary

  in which the condensed system contains four or more hetero rings · CPC title

• C07D471/22

  in which the condensed systems contains four or more hetero rings · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• C07D519/00 Primary

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title